Implicit Bioscience
Implicit Bioscience: Pioneering immunology-based drug development for inflammatory and infectious diseases since 2004.
Founded
2004Implicit Bioscience: Pioneering immunology-based drug development for inflammatory and infectious diseases since 2004.
Implicit Bioscience, founded in 2004 and based in Seattle, Washington, is a clinical-stage drug development company. The company's core mission is to leverage groundbreaking discoveries in immunology to revolutionize the management of inflammatory and infectious diseases. Implicit Bioscience focuses on developing innovative therapies that address significant unmet medical needs, particularly in cardiology and immunology. Their product pipeline includes advanced antibody-based treatments designed to reprogram immune cells involved in heart diseases.
The company has garnered attention through its notable research and development efforts, including a study analyzing over a million patient records to uncover heart failure risks. Implicit Bioscience collaborates with leading experts and institutions to advance its scientific endeavors. Their achievements include the integration of precision nuclear medicine tools to enhance the efficacy of their heart disease treatments. Overall, Implicit Bioscience's impact lies in its potential to transform therapeutic approaches for complex diseases, significantly improving patient outcomes.
Companies similar to Implicit Bioscience include Bitterroot Bio, HI-Bio, Imidomics and KBP Biosciences.
Implicit Bioscience was founded in 2004.
Implicit Bioscience's headquarters is located in Seattle, WA, US.
Implicit Bioscience's most recent funding round was for $65.6k (USD) in August 2020.
As of Aug 28, 2020, Implicit Bioscience has disclosed funding of $17M (USD). Undisclosed round amounts are excluded.
Implicit Bioscience has 31 employees as of Feb 5, 2024.
KBP Biosciences
kbpbiosciences.com
